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1. Main Messages
•	 Many	interventions	for	prevention	have	very	strong	cost-effectiveness	credentials	(43	that	are	either	
dominant	or	cost	less	than	$10,000	per	DALY	prevented).	Such	interventions	should	only	be	ignored	if	
decision-makers	have	very	serious	reservations	about	the	evidence	base	or	are	facing	insurmountable	
problems	in	relation	to	stakeholder	acceptability	or	feasibility	of	implementation.
•	 Another	group	of	preventive	interventions	(31)	are	good	value	for	money	compared	to	the	decision	
threshold	of	less	than	$50,000	per	DALY	prevented.
•	 There	are	also	interventions	for	prevention	that	have	poor	cost-effectiveness	credentials	(38);	have	
an	insufficient	evidence	base	(4);	are	associated	with	more	harm	than	benefit	(‘dominated’:	2);	or	are	
dominated	by	more	cost-effective	alternatives	(2).	It	is	vital	to	recognise	that	prevention	is	not	always	value	
for	money	and	is	not	always	‘better	than	cure’.
•	 A	large	impact	on	population	health	(i.e.	>100,000	DALYs	prevented	per	intervention)	can	be	achieved	
by	a	limited	number	of	cost-effective	interventions:	taxation	of	tobacco,	alcohol	and	unhealthy	foods;	
regulating	the	salt	content	of	processed	food;	improving	the	efficiency	of	blood	pressure-	and	cholesterol-
lowering	drugs;	gastric	banding	for	severe	obesity;	and	an	intensive	SunSmart	campaign.
•	 There	are	more	cost-effective	interventions	with	a	moderate	impact	on	population	health	(between	
10,000	and	100,000	DALYs	prevented	per	intervention).	The	main	missed	opportunities	at	the	national	
level	among	these	are	screening	programs	for	pre-diabetes,	chronic	kidney	disease	and	low	bone	mineral	
density	in	elderly	women.	Smoking	cessation	aids,	pedometers	and	mass	media	for	physical	activity	are	
other	approaches	with	moderate	population	health	impact.	
•	 Of	the	cost-effective	interventions	with	a	smaller	population	health	impact	(<10,000	DALYs	per	
intervention),	the	growing	list	of	potential	preventive	measures	for	mental	disorders	deserves	special	
mention.	
2. Background
In	ACE-Prevention	we	set	out	to	perform	cost-effectiveness	analyses	of	150	interventions.	We	strived	to	
be	comprehensive	in	our	evaluation	of	prevention	of	non-communicable	disease	and	its	main	risk	factors.	
Eventually,	we	selected	and	analysed	123	preventive	interventions.	We	also	completed	analyses	for	27	
treatment	interventions.	
In	this	pamphlet	we	present	the	cost-effectiveness	results	for	each	of	the	individual	preventive	interventions	
in	what	is	often	called	a	league	table	format.	A	big	advantage	of	ACE-Prevention	is	that	all	interventions	
were	analysed	using	common	methods	allowing	valid	comparisons.	The	league	table	is	a	first	sifting	of	
interventions	into	those	that	are	and	are	not	good	value	for	money.	We	also	indicate	the	relative	size	of	the	
annual	intervention	costs	and	the	amount	of	health	gain	projected	over	the	lifetime	of	the	2003	Australian	
population	receiving	the	interventions.	If	other	important	policy	considerations	might	facilitate	or	hinder	the	
implementation,	these	are	raised.
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This	approach	is	not	fully	informative	for	two	reasons.	First,	some	interventions	appear	cost-effective	when	analysed	in	isolation	but	have	
more	efficient	alternatives.	Second,	the	one-by-one	analyses	do	not	take	into	account	that	many	interventions	are	not	implemented	
in	isolation.	When	combinations	of	interventions	are	analysed,	care	must	be	taken	not	to	double-count	shared	costs	and	benefits.	The	
latter	tends	to	be	the	more	important	consideration:	other	interventions	in	the	chosen	package	reduce	disease	rates	and	any	additional	
intervention	cannot	claim	the	same	reduction.	The	pamphlets	on	specific	topic	areas	(such	as	blood	pressure	and	cholesterol-lowering,	
alcohol,	physical	inactivity,	body	mass	and	kidney	disease)	present	the	most	cost-effective	‘optimal’	mix	to	address	a	health	problem.	
Another	pamphlet	shows	the	combined	impact	of	the	most	cost-effective	prevention	intervention	options	across	all	topic	areas.	
3. league taBle categories
For	clarity	of	presentation,	we	have	‘triaged’	our	cost-effectiveness	results	into	five	categories	and	then	within	each	category	reported	
on	broader	issues	that	impact	on	policy	decisions.	In	ACE–Prevention	we	assume	a	decision	threshold	of	‘$50,000	per	DALY	prevented’	to	
determine	whether	an	intervention	is	‘cost-effective’	or	not.	The	categories	are:	
•	 Dominant:	interventions	that	both	improve	health	and	achieve	net	cost	savings;	
•	 Very Cost-Effective:	interventions	that	improve	health	at	a	cost	of	less	than	$10,000	per	DALY	prevented;	
•	 Cost-Effective:	interventions	that	improve	health	at	a	cost	of	between	$10,000	and	$50,000	per	DALY	prevented;	
•	 Not Cost-Effective:	interventions	that	improve	health	at	a	cost	of	more	than	$50,000	per	DALY	prevented;	and	
•	 Dominated:	interventions	for	which	more	cost-effective	alternatives	are	available.	
The	results	for	123	preventive	interventions	evaluated	are	classified	by	triage	category.	Full	documentation	(including	treatment	
interventions	and	multiple	variations	of	some	interventions)	are	provided	in	Appendix	2	of	the	main	report.	The	following	is	the	key	to	
reading	the	results	tables:
DALY,	disability-adjusted	life	year
4. results
4.1  results classified By size of HealtH iMpact
A	large	impact	on	population	health	(i.e.	>100,000	DALYs	prevented	per	intervention)	can	be	achieved	by	a	limited	number	of	cost-
effective	interventions	(Table	1):	
•	 taxation	of	tobacco,	alcohol	and	unhealthy	foods;	
•	 a	mandatory	limit	on	salt	in	just	three	basic	food	items	(bread,	cereals	and	margarine);	
•	 improving	the	efficiency	of	blood	pressure-	and	cholesterol-lowering	drugs	using	an	absolute	risk	approach	and	choosing	the	most	
cost-effective	generic	drugs	(or	potentially	introducing	a	low-cost	polypill	that	combines	three	blood-pressure-lowering	drugs	and	
one	cholesterol-lowering	drug	into	one	single	pill);	
•	 gastric	banding	for	severe	obesity;	and	
•	 an	intensive	SunSmart	campaign.	
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receiving the interventions. If other important policy considerations might facilitate or hinder 
the implementation, these are raised. 
This approach is not fully informative for two reasons. First, some interventions appear cost-
effective when analysed in isolation but have more efficient alternatives. Second, the one-by-
one analyses do not take into account that many interventions are not implemented in 
isolation. When combinations of interventions are analysed, care must be taken not to 
double-count shared costs and benefits. The latter tends to be the more important 
consideration: other interventions in the chosen package reduce disease rates and any 
additional interventio  cannot claim the same reduction. The pamphl ts o  pecific topic 
areas (such as blood pressure and cholesterol-lowering, alcohol, physical inactivity, body 
mass and kidney disease) present the most cost-effective ‘optimal’ mix to address a health 
problem. Another pamphlet shows the combined impact of the most cost-effective prevention 
intervention options across all topic areas.  
 
3. League table categories 
For clarity of presentation, we have ‘triaged’ our cost-effectiveness results into five categories 
and then within each category reported on broader issues that impact on policy decisions. In 
ACE–Prevention we assume a decision threshold of ‘$50,000 per DALY prevented’ to 
determine whether an intervention is ‘cost-eff ctiv ’ o  not. The categories are:  
• Dominant: interventions that both improve health and achieve net cost savings;  
• Very Cost-Effective: interventions that improve health at a cost of less than $10,000 per 
DALY prevented;  
• Cost-Effective: interventions that improve health at a cost of between $10,000 and 
$50,000 per DALY prevented;  
• Not Cost-Effective: interventions that improve health at a cost of more than $50,000 per 
DALY prevented; and  
• Dominated: interventions for which more cost-effective alternatives are available.  
Th  results for 123 preventive interventions evalu ted r  classifie  by triage category. Full 
documentation (including treatment interventions and multiple variations of some 
interventions) are provided in Appendix 2 of the main report. The following is the key to 
reading the results tables: 
Key to results 
Health impact  
(lifetime)  Small 
0–10,000 DALYs  
 
Medium 
10,000–100,000 DALYs 
 
Large 
>100,000 DALYs 
Intervention cost  
(annual) Small 
<$10 million 
Medium 
$10–100 million 
 
Large 
>$100 million  
DALY, disability-adjusted life year 
 
  
+ ++ +++
+ ++ +++
The	evidence	base	is	‘likely’	for	the	taxation	and	regulation	interventions,	‘sufficient’	for	the	treatment	interventions	and	‘limited’	for	
SunSmart	(based	on	a	comparison	of	skin	cancer	rates	between	states).	Taxation	and	regulation	changes	have	low	implementation	costs,	
but	do	involve	‘political	costs’	that	require	political	will	to	overcome.	The	proposed	changes	for	blood	pressure	and	cholesterol	involve	
stakeholder	acceptability	issues	for	practitioners	that	would	need	to	be	carefully	managed.	Government	subsidies	for	gastric	banding	
would	need	to	be	accompanied	by	explicit	guidelines,	e.g.	restricting	access	to	people	with	severe	obesity	who	have	demonstrably	failed	
to	lose	weight	by	diet	and	exercise.
Table	1:		Lifetime	health	outcomes,	intervention	costs	and	cost	offsets	for	the	most	cost-effective	preventive	interventions	with	the	
largest	population	health	impact
DALY,	disability-adjusted	life	year
*	We	estimate	a	lifetime	health	benefit	of	230,000	DALYs	prevented	from	current	practice.	The	polypill	or	a	combination	of	blood-pressure-lowering	drugs	targeting	by	
absolute	cardiovascular	disease	risk	and	‘realistic’	assumptions	on	uptake	and	adherence	would	lead	to	large	cost	savings	and	some	greater	health	gain	additional	to	the	
230,000	DALYs	of	current	practice	(hence	we	classify	these	as	interventions	with	a	large	impact	greater	than	100,000	lifetime	DALYs).
†	The	current	practice	of	blood	pressure-	and	cholesterol-lowering	treatments	is	inefficient	and	hence	the	negative	costs	(i.e.	cost	savings)	if	replaced	by	more	efficient	
treatment.
There	are	more	cost-effective	interventions	with	a	moderate	impact	on	population	health	(between	10,000	and	100,000	DALYs	
prevented	per	intervention).	The	main	missed	opportunities	at	the	national	level	among	these	are	screening	programs	for	pre-diabetes,	
chronic	kidney	disease	and	low	bone	mineral	density	in	elderly	women.	There	is	good	evidence	for	the	effectiveness	of	the	drug	and	
lifestyle	treatments	that	are	recommended	for	the	high-risk	individuals	identified	by	such	screening	programs.	Smoking	cessation	
aids,	pedometers	and	mass	media	for	physical	activity	are	other	approaches	with	moderate	population	health	impact.	We	note	that	a	
considerable	health	impact	of	physical	activity	can	be	achieved	without	reducing	body	weight.	
Of	the	cost-effective	interventions	with	a	small	population	health	impact	(<10,000	DALYs	per	intervention),	the	growing	list	of	potential	
preventive	measures	for	mental	disorders	deserves	special	mention.	Hepatitis	B	and	HPV	vaccination	are	cost-effective	measures	for	
preventing	cirrhosis	and	cancers.
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Table 1:  Lifetime health outcomes, intervention costs and cost offsets for the most cost-effective 
preventive interventions with the largest population health impact 
 (Lifetime, discounted)  
Intervention DALYs prevented 
Intervention 
costs 
(A$ billion) 
Cost offsets 
(A$ billion) 
Taxation    
Tobacco tax 30% 270,000 0.02 –0.7 
Alcohol tax 30% 100,000 0.02 –0.5 
Alcohol volumetric tax 10% above current 
excise on spirits 110,000 0.02 –0.7 
Unhealthy foods tax 10% 170,000 0.02 –3.5 
Regulation    
Mandatory salt limits on processed food 110,000 0.07 –1.5 
Preventive treatments    
Three blood-pressure-lowering drugs to 
replace current practice of preventive drug 
treatments* 
20,000 –1.9† –0.3 
Polypill to replace current practice*  60,000 –7.0† –0.8 
Laparoscopic gastric banding (body mass 
index >35) 140,000 3.7 –2.9 
Health promotion    
Intensive SunSmart  120,000 2.0 –0.3 
 
DALY, disability-adjusted life year 
*  estimate a lif time h alth benefit of 230,000 DALYs p vented from current practice. The p lypill or a 
combination of blood-pressure-lowering drugs targeting by absolute cardiovascular disease risk and ‘realistic’ 
assumptions on uptake and adherence would lead to large cost savings and some greater health gain additional 
to the 230,000 DALYs of current practice (hence we classify these as interventions with a large impact greater 
than 100,000 lifetime DALYs). 
† The current practice of blood pressure- and cholesterol-lowering treatments is inefficient and hence the negative 
costs (i.e. ost savings) if replaced by ore fficient treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2  results classified By cost-effectiVeness ratio
Dominant (cost-saving) interventions 
Twelve	of	the	23	dominant	prevention	interventions	have	a	population-wide	focus	aiming	to	reduce	exposure	to	harmful	risk	factors	
and	behaviours	by	taxation	(of	alcohol,	tobacco	and	unhealthy	food)	or	regulation	(alcohol	advertising	bans,	raising	minimum	age	
of	drinking,	limiting	salt	in	processed	food	and	fluoridation	of	drinking	water).	Four	others	are	health	promotion	interventions	that	
advocate	physical	activity	and	fruit	and	vegetable	consumption	or	address	cardiovascular	health	in	general.	The	remaining	seven	are	
screening	interventions	targeting	treatment	to	those	at	high	risk	(Table	2).	These	seven	interventions	address	cardiovascular	disease,	
chronic	kidney	disease,	suicide,	psychosis	and	liver	cirrhosis	or	liver	cancer	as	long-term	consequences	of	hepatitis	B.	
Table	2:	Dominant	(cost-saving)	preventive	interventions	for	non-communicable	disease,	ACE-Prevention
ACE,	angiotensin-converting	enzyme;	CVD,	cardiovascular	disease
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Table 2: Dominant (cost-saving) preventive interventions for non-communicable disease, ACE-
Prevention 
Topic area Intervention Lifetime 
health 
impact 
Annual 
interventio
n cost 
Strength of 
evidence 
Alcohol Volumetric tax ++ + Likely 
 Tax increase 30% +++ + Likely 
 Advertising bans + + Limited 
 Raise minimum legal drinking age to 21 + + Limited 
Tobacco Tax increase 30% (with or without indexation) +++ + Likely 
Physical activity Pedometers ++ ++ Sufficient 
Mass media ++ ++ Inconclusive 
Nutrition Community fruit and vegetable intake 
promotion 
+ ++ May be effective 
 Voluntary salt limits + + Likely 
 Mandatory salt limits +++ + Likely 
Body mass 10% tax on unhealthy food +++ + May be effective 
Blood pressure 
and cholesterol 
Community heart health program ++ + May be effective 
Polypill $200 for >5% CVD risk +++ +++ Likely 
Osteoporosis  Screen women age 70+ and alendronate ++ ++ Sufficient 
Hepatitis B Vaccine and immunoglobulin to infants born to 
carrier or high-risk mothers 
+ + Sufficient 
 High-risk infant vaccination + + Sufficient 
 Selective vaccination of infants with mothers 
from highly endemic countries 
+ + Sufficient 
Kidney disease Proteinuria screen and ACE inhibitors for 
diabetics 
++ + Sufficient 
Mental 
disorders 
Problem-solving post-suicide attempt + + Sufficient 
Treatment for individuals at ultra-high risk for 
psychosis 
+ + Likely 
Oral health Fluoridation drinking water, non-remote  + + Limited 
 
ACE, angiotensin-converting enzyme; CVD, cardiovascular disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Very cost-effective interventions ($0–10,000 per daly) 
Fifteen	of	the	20	very	cost-effective	preventive	interventions	(with	a	cost-effectiveness	ratio	less	than	$10,000	per	DALY)	are	
interventions	that	involve	screening	people,	either	in	primary	care	or	in	schools,	for	severe	obesity,	physical	inactivity,	hazardous	
or	harmful	alcohol	use	or	increased	risk	of	cardiovascular	disease	or	symptoms	of	mental	disorders.	The	screen	is	followed	by	
pharmacological,	psychological,	health	promotional	or	surgical	intervention.	Two	more	interventions	in	this	category	are	of	a	regulatory	
nature	(licensing	controls	of	alcohol	outlets	and	responsible	media	reporting	of	suicides).	A	further	two	interventions	are	in	health	
education	(for	physical	activity	and	fruit	and	vegetable	intake),	and	a	universal	infant	vaccination	intervention	is	also	in	this	category	
(Table	3).	
Table	3	Very	cost-effective	preventive	interventions	($0–10,000	per	DALY)	for	non-communicable	disease,	ACE–Prevention	
ACE,	angiotensin-converting	enzyme;	CCB,	calcium	channel	blocker;	CVD,	cardiovascular	disease;	HBV,	hepatitis	B	virus
Cost-effective interventions ($10,000–50,000 per DAlY)
Among	the	28	cost-effective	interventions	with	a	cost-effectiveness	ratio	between	$10,000	and	$50,000	per	DALY,	one	is	of	a	regulatory	
nature	(enforcement	of	laws	on	driving	under	the	influence	of	alcohol)	and	four	concern	health	education	(addressing	drink	driving,	
fruit	and	vegetable	intake,	physical	activity	and	skin	cancer).	The	remaining	23	are	targeted	interventions	following	a	screen	to	identify	
those	with	high	levels	of	lifestyle-related	diseases,	cervical	cancer	or	symptoms	of	mental	disorders	(Table	4).	The	level	of	evidence	for	
the	health	promotional	interventions	was	judged	to	be	limited	while	all	the	targeted	interventions	in	this	category	had	sufficient	or	likely	
evidence	to	support	effectiveness.	
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Table 3 Very cost-effective preventive interventions ($0–10,000 per DALY) for non-communicable disease, 
ACE–Prevention  
Topic area Intervention Lifetime 
health 
impact 
Annual 
intervention 
cost 
Strength of 
evidence 
Alcohol Brief alcohol intervention GP with or without 
telemarketing and support 
+ + Sufficient 
 Licensing controls + + Likely 
Tobacco Cessation aid: varenicline ++ +++ Sufficient 
 Cessation aid: bupropion ++ +++ Sufficient 
 Cessation aid: nicotine replacement therapy ++ ++ Sufficient 
Physical activity GP Green Prescription + +++ Limited 
 Internet intervention + ++ Sufficient 
Nutrition Information mail-out, multiple re-tailored to 
promote fruit and vegetable intake 
+ + Limited 
Body mass Gastric banding for severe obesity +++ +++ Sufficient 
Blood pressure 
and cholesterol 
Low-dose diuretics >5% CVD risk +++ +++ Sufficient 
Polypill $200 to ages55+ +++ +++ Likely 
CCBs >10% CVD risk ++ ++ Sufficient 
 ACE inhibitors >15% CVD risk ++ ++ Sufficient 
Mental disorders 
drugs/suicide 
Screen and bibliotherapy to prevent adult 
depression  
+ ++ Likely 
Screen and psychologist to prevent 
childhood/adolescent depression 
+ ++ Sufficient 
 Screen and bibliotherapy to prevent 
childhood/adolescent depression 
+ + Limited 
 Responsible media reporting for the reduction of 
suicide 
+ + Likely 
 Parenting intervention for the prevention of 
childhood anxiety disorders 
+ + Sufficient 
Other Universal infant HBV vaccination + ++ Sufficient 
ACE, angiotensin-converting enzyme; CCB, calcium channel blocker; CVD, cardiovascular disease; HBV, 
hepatitis B virus 
 
 
 
 
 
 
  
 
Table	4		Cost-effective	preventive	interventions	($10,000–50,000	per	DALY)	for	non-communicable	disease,	ACE-Prevention
ACE,	angiotensin-converting	enzyme;	CBT,	cognitive	behaviour	therapy;	CCB,	calcium	channel	blocker;	CVD,	cardiovascular	disease;	HPV,	human	papillomavirus
Cost-ineffective interventions (>$50,000 per DAlY)
Cost-ineffective	preventive	interventions	include	the	majority	of	fruit	and	vegetable	interventions,	dietary	advice	on	salt	and	a	multiple-
component	intervention	addressing	diet,	weight	and	exercise	(Table	5).	Each	of	these	has	poor	effectiveness	and	some	have	high	cost.	
The	commercial	Weight	Watchers	program	is	not	cost-effective	as	there	is	poor	maintenance	of	weight	loss.	The	high	cost	of	orlistat	and	
sibutramine	makes	them	cost-ineffective.	
Raloxifene	has	not	been	shown	to	prevent	hip	fractures	and	is	too	expensive	a	drug	to	be	considered	for	prevention	of	osteoporosis.	
Aspirin	has	been	considered	for	a	long	time	to	be	an	effective	drug	for	preventing	cardiovascular	disease.	As	it	is	cheap,	it	would	become	
one	of	the	most	efficient	options	for	CVD	prevention.	However,	recently	two	studies	showed	no	beneficial	effect	of	aspirin.	As	aspirin	also	
carries	a	risk	of	bleeding	in	the	stomach	and	brain,	particularly	in	the	elderly,	not	using	it	in	primary	prevention	may	be	wiser.	
A	school-based	drug	intervention	had	poor	effectiveness.	The	gun	buy-back	scheme	introduced	after	the	1996	Port	Arthur	massacre	in	
Tasmania	was	very	expensive.	The	drop	in	suicide	that	followed	cannot	be	unequivocally	attributed	to	the	scheme.
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Table 4  Cost-effective preventive interventions ($10,000–50,000 per DALY) for non-communicable 
disease, ACE-Preve tion 
Topic area Intervention Lifetime 
health 
impact 
Annual 
interventio
n cost 
Strength of 
evidence 
Alcohol Drink drive mass media + ++ Limited 
 Roadside breath testing + ++ Likely 
Physical activity TravelSmart + +++ May be 
effective 
 GP referral + +++ Limited 
Nutrition Multiple tailored mailed fruit and vegetable 
promotion 
+ + Limited 
Obesity Diet and exercise for overweight + +++ Sufficient 
 Low-fat diet for overweight + ++ Sufficient 
Blood pressure 
and cholesterol 
Dietary counselling >5% CVD risk by dietitian ++ ++ Sufficient 
Dietary counselling >5% CVD risk by GP ++ ++ Sufficient 
 Phytosterol supplementation >5% CVD risk ++ +++ Sufficient 
 Statins >5% CVD risk +++ +++ Sufficient 
 Statins and ezitimibe >5% CVD risk +++ +++ Sufficient 
 Beta blockers >5% CVD risk ++ +++ Sufficient 
 CCBs >5% CVD risk +++ +++ Sufficient 
 ACE inhibitors >5% CVD risk +++ +++ Sufficient 
Cancer Pap screen (current practice) + ++ Sufficient 
 HPV DNA test screen 3-yearly from age 18 + + Likely 
 HPV vaccination and Pap screen  + ++ Likely 
 HPV vaccination and HPV DNA test screen 3-
yearly from age 18 
+ ++ Likely 
 SunSmart +++ +++ Limited 
Pre-diabetes Screen and dietary advice + ++ Sufficient 
 Screen and exercise physiologist ++ ++ Sufficient 
 Screen and diet + exercise  ++ ++ Sufficient 
 Screen and metformin ++ ++ Sufficient 
 Screen and acarbose ++ ++ Sufficient 
Kidney disease Screen and ACE-inhibitors for non-diabetics 
age >25  
++ ++ Sufficient 
Mental disorders Screen and group CBT to prevent adult 
depression 
+ ++ Likely 
Screen and CBT to prevent post-partum 
depression 
+ + Limited 
ACE, angiotensin-converting enzyme; CBT, cognitive behaviour therapy; CCB, calcium channel blocker; CVD, 
cardiovascular disease; HPV, human papillomavirus 
 
 
 
 
 
 
 
 
 
 
 
 
Table	5		Cost-ineffective	preventive	interventions	(>$50,000	per	DALY)	for	non-communicable	disease,	ACE-Prevention
CVD,	cardiovascular	disease;	HPV,	human	papillomavirus;	MSM,	men	having	sex	with	men
Dominated	interventions	(‘do	more	harm	than	good’	or	‘better	options	available’)
Three	interventions	fall	in	the	category	of	dominated	interventions	(Table	6).	The	first	is	prostate-specific	antigen	(PSA)	testing	to	screen	
for	prostate	cancer.	A	large	proportion	of	false	positive	test	results	means	a	greater	number	of	expensive	and	unpleasant	follow-up	
diagnostic	procedures	and,	in	some	cases,	unnecessarily	aggressive	treatments	for	a	disease	that	may	never	give	symptoms	during	an	
individual’s	lifetime.	These	harmful	effects	are	greater	than	the	modest	population	health	gain	from	detecting	true	cases	of	prostate	
cancer.	While	there	is	no	official	PSA	screening	program,	there	is	an	extensive	level	of	de	facto	screening.	
Table	6	Dominated	interventions,	ACE-Prevention
PSA,	prostate-specific	antigen
The	second	dominated	intervention	is	rosiglitazone	for	people	identified	with	pre-diabetes.	It	is	associated	with	an	increased	risk	of	
cardiovascular	disease.	Third,	beta	blockers,	while	effective	in	preventing	cardiovascular	disease,	compete	with	three	more	cost-effective	
blood-pressure-lowering	drugs.	Combining	more	than	three	such	drugs	is	against	clinical	practice.	Lastly,	dietary	advice	by	a	GP	is	
dominated	by	dietary	advice	provided	by	a	dietician.
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Table 5  Cost-ineffective preventive interventions (>$50,000 per DALY) for non-communicable disease, 
ACE-Prevention 
Topic area Intervention Comments 
Diet Fruit and vegetable interventions targeting 
individuals (except tailored mailings) 
Poor effectiveness 
  Fruit and vegetable interventions at workplace Poor effectiveness 
  Dietary advice on salt Poor effectiveness and high cost 
  Weight Watchers Poor maintenance of weight loss 
  Multi-component diet/physical activity/weight 
intervention 
Poor effectiveness 
  Orlistat, sibutramine Too expensive 
Osteoporosis Raloxifene No effect on hip fractures and too 
expensive 
Cancer Combined Pap and HPV DNA test screen 3-
yearly from age 18 
No benefit from start at age 18 
instead of 25 
 HPV vaccination and combined Pap and HPV 
DNA test screen 3-yearly from age 18 
No benefit from start at age 18 
instead of 25 
 Anal cytology for MSM Expensive screen for rare cancer 
Pre-diabetes Screen and orlistat Too expensive 
 Screen and rosiglitazone Too expensive 
CVD Aspirin Risk of bleeding and ambiguous 
evidence for effect in primary 
prevention 
Vision loss Ranibizumab for age-related macular 
degeneration 
Too expensive 
Mental 
health/drugs 
  
School-based drug intervention Poor effectiveness 
Gun buy-back and legislation changes to reduce 
suicides 
Only ecological evidence for 
reduction in suicide; high cost 
Shingles Varicella zoster vaccination at age 50 Low frequency of shingles; 
expensive 
CVD, cardiovascular disease; HPV, human papillomavirus; MSM, men having sex with men 
 
 
 
 
 
 
 
Table 6 Dominated interventions, ACE-Prevention 
Topic area Intervention Comments 
Cancer Prostate cancer screen by PSA More harm than benefit 
Diabetes Screen and rosiglitazone Adverse effect on cardiovascular 
disease 
Blood pressure and 
cholesterol 
Beta blockers Three more efficient drugs in class 
Dietary advice by a GP Less expensive option 
PSA, prostate-specific antigen 
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ACE–PrEvEntion PAmPhlEts
5. aBout ace-preVention
To aid priority setting in prevention, the Assessing Cost-Effectiveness in Prevention Project (ACE-Prevention) applies 
standardised evaluation methods to assess the cost-effectiveness of 100 to 150 preventive interventions, taking a health 
sector perspective. This information is intended to help decision-makers move resources from less efficient current 
practices to more efficient preventive action resulting in greater health gain for the same outlay.
Indigenous population results 
1.   Cardiovascular disease prevention 
2.   Diabetes prevention 
3.   Screening and early treatment of chronic kidney disease
Overall results 
1.   League table 
2.   Combined effects 
paMpHlets in tHis series 
Methods: 
A.   The ACE-Prevention project 
B.   ACE approach to priority setting 
C.   Key assumptions underlying the economic analysis 
D.   Interpretation of ACE-Prevention cost-effectiveness results 
E.   Indigenous Health Service Delivery 
general population results
1.		 Adult	depression
2.		 Alcohol
3.		 Blood	pressure	and	cholesterol	lowering
4.		 Cannabis
5.		 Cervical	cancer	screening,	Sunsmart	and	PSA	screening
6.		 Childhood	mental	disorders
7.		 Fruit	and	vegetables
8.	 HIV
9.	 Obesity
10.	 Osteoporosis
11.	 Physical	activity
12.	 Pre	diabetes	screening
13.	 Psychosis
14. Renal replacement therapy, screening and early treatment of chronic kidney disease
15. Salt
16. Suicide prevention
17. Tobacco 
